Investigational Gene Therapy for Adults with CF

 

Trial Objective

Investigational Gene Therapy for Adults with CFThis study is designed to test the safety of 4D-710, an investigational gene therapy drug for adults with cystic fibrosis (CF) who are unable to use CFTR modulators. Adeno-associated viruses (AAV) are small viruses that are commonly found in nature and are not known to cause disease in humans.  4D-710 is an AAV that was changed in the laboratory to deliver a copy of the CFTR gene to the lungs, thereby providing a copy of instructions for making normal CFTR protein. Participants will use a nebulizer to inhale 4D-710 into the lungs to see if 4D-710 is safe for use in adults with cystic fibrosis and to see if 4D-710 can help lung function.

Enrollment

Active Clinical Trials Currently Recruiting

Who Can Participate

Adults with CF who are not eligible for CFTR modulatory therapy or discontinued CFTR modulator therapy due to side effects.

Age: 18+    Gender: Any Gender


Estimated Time Commitment

24 months

Year 1: 10 scheduled in-person visits. Year 2: Long-term follow up, phone check in.



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Trish Smith

Samantha Johnson
303.270.2598

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

4D Molecular Therapeutics, Inc.

Principal Investigators

Co-Investigators


Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.


*
*
*
*
 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: